In the phase III ENSURE trial [13], which evaluated the efficacy and safety of first-line erlotinib as compared to chemotherapy with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer (NSCLC) harboring an EGFR activating mutation, plasma samples were collected from 517 patients. This evidence concerns the gene EGFR and non-small cell lung carcinoma.